- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04972708
Genetics of COVID-19 Risks & Resilience in Bipolar Disorder (BIPCOVID)
Genetics of COVID-19 Risks & Resilience in Bipolar Disorder as Subproject of BIPGEN (Genetic Changes in Bipolar Disorder)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Methods: BIPGEN is a cross-sectional study on the genetics of bipolar disorder (BD). BIPGEN includes a personality questionnaire (TEMPS-A). DNA is isolated in the BIPGEN study from fasting blood with the QUIASYMPHONY robot from study participants with Bipolar Disorder (diagnosis according to DSM-IV) and healthy controls. The DNA is then genotyped with classic genotyping arrays (GWAS array). The aim of BIPGEN is to associate genetic variants (single-nucleotide-polymorphisms/ SNPs or copy-number-variations/CNVs) with bipolar affective disorder.
A subproject of BIPGEN is the BIP-COVID project, which is a cross-sectional genetics study about risks & resilience in the COVID-19 pandemic in BD and healthy controls at the Medical University of Graz. Study participants with BD and controls from the well-established BIPLONG and BIPGEN studies will undergo a special BIP-COVID visit, which will include a COVID-19 specific online Lime survey about the psychological burden in the COVID-19 crisis, a COVID-19 antibody test (IgM and IgG), inflammation markers and isolation of DNA from fasting blood. Genotyping of DNA will be done with the GSA V.3 array. Genetic analyses (Polygenic Risk Scores of I. Stress or Major Depression and II. COVID-19 infection established with the programs PLINK, PRSice and R) will be used to analyze the genetic mechanisms of COVID-19 pandemic associated psychological symptoms and COVID-19 infection risk. Systems biology methods will be used to depict protective pathways against COVID-19 infection (e.g. Lithium pathways) and against COVID-19 associated psychiatric symptoms
Aim:
- We aim at analyzing the neuropsychological and genetic underpinning of COVID-19 associatedreactive psychiatric symptoms in BD and in healthy controls.
- We aim at analyzing genetic predictors of COVID-19 infection in BD and in controls.
- We aim at analyzing the protective effects of the GSK-3β inhibitor lithium against COVID-19 infection.
Intervention: Cross-sectional genetics study
Key inclusion and exclusion criteria: Inclusion criteria are written consent after previous written and verbal information, diagnosis of BD according to DSM-IV and age between 18 and 75 years. Exclusion criteria include acute suicidality, lack of consent, severe active drug dependence (i.e., alcohol, benzodiazepines, morphine), other currently active severe mental / cerebral organic disease (e.g. epilepsy, brain tumor), severe skull-brain trauma / brain surgery in the past, known florid tumor disease, congenital / infantile mental retardation, dementia (from Mini-Mental State Examination (MMSE) 20), severe florid autoimmune diseases or current immunosuppression (e.g., lupus erythematosus, HIV (human immunodeficiency virus), multiple sclerosis), cardiac, renal and pulmonary disorders or PTSD (post-traumatic stress disorder) or anxiety.
Healthy controls do not have a history of mental disorder and do not have first- or second-degree relatives with psychiatric disorders.
Primary and secondary endpoint(s) of the BIPCOVID project:
The primary endpoint is PRS of stress, the secondary endpoint is PRS of COVID-19 risk.
Sample size, statistical analyses, power calculation: The program G*Power (Version 3.1) was used for the calculation of the number of cases. Linear bivariate regression analyses for two groups (BD and control cohort) will be calculated with the results from psychological/psychiatric inventories as predictors (e.g. Pittsburgh Sleep Quality Index, Mediterranean Diet Score, Resilience Scale) and the three PRS as criterion. G*Power calculates for a linear bivariate regression, with a Δ slope of 0.03, α = .05 and a power of 95 % a total sample size of 364 persons.
Trial duration of BIPCOVID: 3 years.
Participating centers: The BIP-COVID sample will be recruited as monocentric study at the special outpatient department for Bipolar Disorders (managed by Univ.Prof. Eva Reininghaus) at the Department of Psychiatry and Psychotherapeutic Medicine at the Medical University of Graz, Austria. Psychiatric genetics and bioinformatics experts from the University of Basel, the University of Marburg, the University of Bonn, the Karolinska Institutet & Medical University of Vienna & CAMH Toronto will supervise the KLIF-funded doctoral student and will support the state-of-the-art bioinformatics analyses.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studiekontakt
- Namn: Eva Reininghaus, MD, PhD, MBA
- Telefonnummer: +43 316 385 80968
- E-post: eva.reininghaus@medunigraz.at
Studieorter
-
-
Styria
-
Graz, Styria, Österrike, 8036
- Rekrytering
- Medical University Graz
-
Kontakt:
- Eva Reininghaus, MD, PhD, MBA
- Telefonnummer: +43 316 385 80968
- E-post: eva.reininghaus@medunigraz.at
-
Kontakt:
- Susanne Bengesser, MD, PhD, BSc
- Telefonnummer: +43 316 385 86224
- E-post: susanne.bengesser@medunigraz.at
-
Underutredare:
- Nina Dalkner, PhD
-
Underutredare:
- Susanne Bengesser, MD, PhD, BSc
-
Huvudutredare:
- Eva Reininghaus, MD, PhD, MBA
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Inclusion criteria are written consent after previous written and verbal information, diagnosis of BD according to DSM-IV and age between 18 and 75 years.
Exclusion Criteria:
Exclusion criteria include
- acute suicidality
- lack of consent
- severe active drug dependence (i.e., alcohol, benzodiazepines, morphine)
- other currently active severe mental / cerebral organic disease (e.g. epilepsy, brain tumor),
- severe skull-brain trauma / brain surgery in the past,
- known florid tumor disease,
- congenital / infantile mental retardation,
- dementia (from MMSE 20),
- severe florid autoimmune diseases or current immunosuppression (e.g., lupus erythematosus, HIV, multiple sclerosis),
- cardiac, renal and pulmonary disorders or PTSD or anxiety
- Healthy controls do not have a history of mental disorder and do not have first- or second-degree relatives with psychiatric disorders.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: Kohort
- Tidsperspektiv: Blivande
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Bipolar Disorder
100 patients after COVID-19 infection 100 patients without COVID-19 infection
|
Cross-sectional genetics study
|
Healthy controls
100 controls after COVID-19 infection 100 controls without COVID-19 infection
|
Cross-sectional genetics study
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
PRS of stress or depression
Tidsram: 3 Years
|
genetic sum score for depression (polygenic risk score)- the higher the score, the higher the risk
|
3 Years
|
PRS of COVID-19 infection
Tidsram: 3 Years
|
genetic sum score for COVID-19 infection (polygenic risk score)- the higher the score, the higher the risk
|
3 Years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Patologiska processer
- Coronavirusinfektioner
- Coronaviridae-infektioner
- Nidovirales infektioner
- RNA-virusinfektioner
- Virussjukdomar
- Infektioner
- Luftvägsinfektioner
- Luftvägssjukdomar
- Lunginflammation, Viral
- Lunginflammation
- Lungsjukdomar
- Bipolära och relaterade sjukdomar
- Covid-19
- Sjukdom
- Bipolär sjukdom
Andra studie-ID-nummer
- 23-199 ex 10/11
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Covid19
-
Henry Ford Health SystemAvslutad
-
Ricardo Pereira MestreInstitute of Oncology Research (IOR); Istituto Cantonale di PatologiaAvslutad
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos III; Spanish Clinical Research Network - SCReNAktiv, inte rekryterande
-
Inmunova S.A.Hospital Italiano de Buenos Aires; Laboratorio Elea Phoenix S.A.; Hospital... och andra samarbetspartnersAvslutad
-
Manchester University NHS Foundation TrustUniversity of ManchesterAvslutad
-
Rush University Medical CenterHospital Civil de GuadalajaraAvslutadCovid19Förenta staterna, Mexiko
-
Evelyne D.TrottierAvslutad
-
Sinovac Research and Development Co., Ltd.Avslutad
-
Mabwell (Shanghai) Bioscience Co., Ltd.Shanghai Public Health Clinical CenterAvslutad
-
Anavasi DiagnosticsHar inte rekryterat ännu